Robert Penfold, PhD, is a health services research and health policy expert whose work focuses on developing and testing strategies to optimize behavioral health care delivery and patient outcomes—particularly in children and adolescents. His research addresses practical issues, such as how to reduce unnecessary use of antipsychotic medications in youth. He also studies the effects of cost-control policies on how clinicians deliver care, how people use care, and how those changes can promote or worsen their health.
Dr. Penfold is a co-investigator in the Mental Health Research Network (MHRN), a resource for studies on mental health conditions ranging from autism to postnatal depression. He leads the MHRN’s child and adolescent scientific interest group. He is also investigating reasons why similar patients receive different mental health treatment, such as different medications, depending on where they live or receive care.
His other recent and ongoing projects include:
Dr. Penfold has extensive experience gathering and analyzing information from large health databases, including those of Medicare, Medicaid, and the Health Care Systems Research Network’s Virtual Data Warehouse. These data and analyses allow rapid information sharing among Kaiser Permanente Washington and participating sites, which improves patient safety and timely access to effective, cutting-edge therapies.
He has also conducted several novel pragmatic clinical trials using the Epic electronic health record system.
Before joining KPWHRI in 2010, Dr. Penfold held research and teaching positions at Nationwide Children's Hospital in Columbus, Ohio; the Winnipeg Regional Health Authority; the Manitoba Centre for Health Policy; and most recently, at Harvard Medical School in the Department of Population Medicine and Harvard Pilgrim Health Care Institute.
Children and adolescents; anti-psychotics and anti-depressants; bipolar disorder, and depression
Comparative effectiveness; consumer-directed health plans; patient outcomes; costs of chronic illnesses; Medicare and Medicaid
Space-time surveillance; interrupted time series analysis
Penfold RB, Thompson EE, Hilt RJ, Kelleher KJ, Schwartz N, Beck A, Clarke G, Ralston JD, Hartzler AL, Coley RY, Akosile M, Vitiello B, Simon GE. Safer Use of Antipsychotics in Youth (SUAY) pragmatic trial protocol. Contemp Clin Trials. 2020 Oct 19:106184. doi: 10.1016/j.cct.2020.106184. Online ahead of print. PubMed
Xi W, Banerjee S, Penfold RB, Simon GE, Alexopoulos GS, Pathak J. Healthcare utilization among patients with psychiatric hospitalization admitted through the emergency department (ED): a claims-based study. Gen Hosp Psychiatry. 2020 Oct 7;67:92-99. doi: 10.1016/j.genhosppsych.2020.10.001. PubMed
Parchman ML, Anderson ML, Penfold RB, Kuo E, Dorr DA. The ability of practices to report clinical quality measures: more evidence of the size paradox? J Am Board Fam Med. Jul-Aug 2020;33(4):620-625. doi: 10.3122/jabfm.2020.04.190369. PubMed
Richards JE, Shortreed SM, Simon GE, Penfold RB, Glass JE, Ziebell R, Williams EC. Association between patterns of alcohol use and short-term risk of suicide attempt among patients with and without reported suicidal ideation. J Addict Med. 2020 Mar 5. doi: 10.1097/ADM.0000000000000637. [Epub ahead of print]. PubMed
Richards JE, Shortreed SM, Simon GE, Penfold RB, Glass JE, Ziebell R, Williams EC. Short-term risk of suicide attempt associated with patterns of patient-reported alcohol use determined by routine AUDIT-C among adults receiving mental healthcare. Gen Hosp Psychiatry. 2020 Jan-Feb;62:79-86. doi: 10.1016/j.genhosppsych.2019.12.002. Epub 2019 Dec 18. PubMed
A new study shows how a little supplemental support can result in big gains, especially in managing patients’ blood pressure.
Dr. Rob Penfold leads pragmatic trial of new online version of proven program developed by UW colleagues.
Dr. Robert Penfold talks about how his father’s death inspired him to work on advance care planning for people with mild cognitive impairment.
Read about it in Healthy Findings.
Bloomberg Businessweek, Feb. 5, 2019